Table 4.
Summary of previously published series
| Article | Histological subtype | No of samples | Smoking status | Concordance PT/M | Analysis within PT | Concordance within PT | Method | Mutation type | Metastatic sites |
|---|---|---|---|---|---|---|---|---|---|
| Yatabe et al. 2011
[17] |
ADC (77) |
77 |
|
100 |
|
|
qPCR |
L858R |
Lymph nodes |
| Fragment analysis |
DEL19 |
||||||||
| INS20 | |||||||||
| 719X | |||||||||
| Sun et al. 2011
[37] |
ADC (39), SCC (31), ADSQ (6), LCC (4) |
80 |
Ever (49) |
|
|
|
Direct sequencing |
all |
Lymph nodes |
| |
Never (31) |
|
|
|
|||||
| |
Global |
92,5% (74/80) |
|
|
|||||
| Wei et al. 2014
[41] |
ADC (49) |
50 |
Ever (10) |
80% |
|
|
qPCR (commercial kit) |
45 hotspots |
Lymph nodes |
| SCC (1) | |||||||||
| |
Never (40) |
97,5% |
|
|
|||||
| |
Global |
93% (47/50) |
|
|
|||||
| |
|
|
|
|
|||||
| Bai et al. 2013
[36] |
ADC (63) |
85 (45 EGFRmt 40 EGFRwt) |
|
|
1431 foci |
87,1% |
ARMS |
DXS EGFR mutation Kit |
|
| SCC (10) |
1238 foci (foci : capture with laser microdissection 0,1cm2) |
4 cases with 5% - 8% of foci showing mutations |
|||||||
| |
ADSQ (5) |
||||||||
| |
Other (7) |
||||||||
| | |||||||||
| Chang et al. 2011
[42] |
ADC (34) |
56 (27 EGFRmt) |
Ever (29) |
62% |
|
|
Direct sequencing |
all |
Lymph nodes |
| SCC (17) | |||||||||
| |
ADSQ (1) |
Never (23) |
70% |
||||||
| |
Other (1) |
Unknown (4) |
|
||||||
| |
Global |
68% (38/56) |
|||||||
| Schmid et al. 2009
[33] |
ADC (96) |
96 (7 EGFRmt) |
Ever (74) |
|
|
|
Direct sequencing |
L858R (3) |
Lymph nodes |
| DEL19 (3) | |||||||||
| |
Never (22) |
|
INS20 (1) |
||||||
| |
Global |
14% (1/7) |
|||||||
| Gow et al 2009
[34] |
ADC (42) |
67 (35 EGFRmt) |
Ever (26) |
|
|
|
Direct sequencing and ARMS for discordant results |
all |
Brain (25) |
| SCC (21) |
Bone (20) |
||||||||
| |
ADSQ (0) |
(19 with adjuvant treatment before molecular analysis on metastatic site) |
Never (41) |
|
Other (22) |
||||
| |
Other (4) |
Global |
26% (9/35) seq and 57 %(20/35) ARMS |
||||||
| Mattsson et al. 2012
[18] |
ADC (6) |
6 |
|
|
3 foci per tumor (distinct morphologies) |
100% |
Direct sequencing |
L858R and DEL19 |
|
| |
|
|
|
|
|
|
|
|
|
| Kalikaki et al. 2008
[35] |
ADC (20) |
25 (7 EGFRmt) |
Ever (22) |
|
|
|
Direct sequencing |
all |
Brain (3) |
| SCC (2) |
Pleura (5) |
||||||||
| |
ADSQ (0) |
(17 with adjuvant treatment before molecular analysis on metastatic site) |
Never (3) |
|
Lung (9) |
||||
| |
Other (3) |
Global |
14% (1/7) 5 mutations are rare alterations (codons 692-847-746-857) |
Adrenal gland (3) |
|||||
| | |||||||||
| |
Bone (2) |
||||||||
| |
Skin (1) |
||||||||
| |
Liver (1) |
||||||||
| Matsumoto et al. 2006
[43] |
ADC (19) |
19 (12 EGFRmut) |
|
100% |
|
|
Direct sequencing |
L858R, DEL19 |
Brain (19) |
| Yatabe et al. 2011
[17] |
ADC (50) |
50 EGFRmt |
|
|
3 foci per tumor (50) |
100% |
qPCR |
L858R |
|
| Fragment analysis |
DEL19 |
||||||||
| 100 foci per tumor (5) | 100% |
Schematic review of previously published series comparing primary tumor and metastasis or different loci within primary tumor. Tumor type, smoking status, detection methods, mutation tested and metastatic sites are given. PT : primary Tumor, M: metastasis, ADC: adenocarcinoma, SCC: squamous cell carcinoma, ADSQ : adenosquamous carcinoma, LCC: large cell carcinoma mt: mutated, wt : wild type, ARMS: amplification refractory mutation system.